Cencora Q1 EPS $2.87 GAAP, $4.08 adjusted; acquires OneOncology for $4.6B

Cencora, Inc.

2026-Q1 EPS reported $2.87 revenue$85,932,016,000

Revenue $85.9B, +5.5% YoY; GAAP diluted EPS $2.87 vs $2.50 prior year; adjusted diluted EPS $4.08 vs $3.73, +9.4%.
Completed acquisition of OneOncology on Feb 2 for ~$4.6B in cash funded by new debt; operations consolidated in U.S. Healthcare Solutions.
Adjusted operating income guidance raised to growth of 11.5%-13.5% from prior 8%-10%; adjusted EPS guidance reaffirmed at $17.45-$17.75.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.